

Cover Story
Free
The FDA Oncologic Drugs Advisory Committee March 7 voted to accept the metric of “minimal residual disease,” or MRD, as a basis for approval of a drug for the treatment of acute lymphoblastic leukemia.
In Brief
Funding Opportunities
Trending Stories
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Why both somatic and germline genomic profiling are essential for precision oncology
- Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?